SecBot SecBot

KMDA

KAMADA LTD
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001567529 Biotech & Drug Discovery
$8.11 +0.02 (+0.25%)
Nov 16 4:00 PM ET · prev $8.09
Market cap
$469.2M
Small cap
Median target
$14.00
+73% · range $12.00–15.00
1 year
+18.6%
from $6.84 · Nov 17
30 days
+6.6%
from $7.61
52-week range
$6.68–9.31
−13% from high · low Nov 20
Avg volume 20D
119.4K
Nov 3 spike 322.8K
Short interest
165.8K
≈0.3% of shares · −16.1%
Days to cover
2.6
at average volume
Insider net
−$1.7M
0 buyers · 1 seller · since Aug 27
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
21
analyzed by SecBot
SecBot read BULLISH 11 reports · 90 days
Balance 0 bearish · 4 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 10/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $1.7M.

  • InstitutionsBULLISH

    Q3 2026: 12 added (0 new), 2 trimmed or exited.

  • Short sellersCOVERING

    Short interest −16.1% to 165.8K shares. 2.6 days to cover, ≈0.3% of shares.

  • TrendRANGE

    1% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPDOUBLED188,037$1.6M
JANE STREET GROUP, LLCDOUBLED102,845$870.1K
Quadrature Capital LtdDOUBLED78,654$665.4K
UBS Group AGDOUBLED70,420$595.8K
STIFEL FINANCIAL CORPADD68,524$579.7K
BARCLAYS PLCDOUBLED43,882$371.2K
MORGAN STANLEYADD16,102$136.2K
JPMORGAN CHASE & COTRIM11,353$98.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Dec 2025
12-month targets · 4 analysts

Price is below the lowest target. Median implies +73%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Dec 9, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 15, 2025Benchmark
REITERATE
REITERATEBuy
Mar 21, 2025Benchmark
INITIATE
INITIATEBuy
Mar 6, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Jan 10, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 14, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$1.7M
sold · 1 insider
DateInsiderTypeValue
Sep 14, 2026
Tsur David
Director
Sep 14, 2026
SELL$186.7K
Sep 14, 2026
Livneh Nir
VP, General Counsel
Sep 14, 2026
EXERCISE$53.7K
Sep 14, 2026
Livneh Nir
VP, General Counsel
Sep 14, 2026
TAX W/H$28.9K
Sep 14, 2026
Brenner Yael
VP Quality
Sep 14, 2026
EXERCISE$29.6K
Sep 14, 2026
Brenner Yael
VP Quality
Sep 14, 2026
TAX W/H$11.5K
Sep 14, 2026
Brenner Yael
VP Quality
Sep 14, 2026
EXERCISE$38.5K
Sep 14, 2026
Brenner Yael
VP Quality
Sep 14, 2026
TAX W/H$14.9K
Sep 14, 2026
Brenner Yael
VP Quality
Sep 14, 2026
EXERCISE$32.4K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
165,778
shares short
-16.1%
vs prior settlement
2.6
days to cover
≈0.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 SEC
Kamada reported record Q3 2026 revenue of $52.0M (up 11% YoY) and net income of $8.0M ($0.14/diluted share, up 51%…
6-K · Impact 6/10
Nov 9, 2026 SEC
Kamada reported Q3 2026 revenue of $52.0M (+11% YoY) and EPS of $0.14, beating the $0.13 consensus. The company raised…
PRESS-RELEASE · Impact 6/10
Nov 9, 2026 Earnings
Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TAS
Nov 2, 2026 SEC
Kamada Ltd. filed a Form 6-K announcing that it will release Q3 and nine-month 2026 financial results on November 9…
6-K · Impact 2/10
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · DOUBLED
188,037 shares ($1.6M)
Sep 30, 2026 Inst.
JANE STREET GROUP, LLC · DOUBLED
102,845 shares ($870.1K)
Sep 14, 2026 Insider
Tsur David sold 22,827 shares
Director @ $8.18 ($186.7K)
Sep 14, 2026 Insider
Livneh Nir acquired via exercise 10,000 shares
VP, General Counsel @ $5.37 ($53.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

21 filings · 4 press releases · 9 bullish · 1 bearish · 11 neutral
All KMDA filing & press-release reports (25)